Drug
GS-9451 clinical trials
Also written GS-9451.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How studies write it
Studies that test it under each name
Development codes
- GS-9451
- 5
Studies by the year they started
6 studies that test it; most in 2011 (4)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 4 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 1
Gilead Sciences (5) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Often tested with
Tested in the same studies.
Ledipasvir (3) · Ribavirin (2) · Tegobuvir (2) · GS-9669 (1) · Peginterferon alfa-2a (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Studies
Open first, then newest update. How each study uses GS-9451 is read from its arms, and is right about nine times in ten.
Testing it · 6
- Combination Therapy for Chronic Hepatitis C InfectionCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT01805882Written as GS-9451
- Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus InfectionCompletedPhase 2Gilead SciencesNCT01371578Written as GS-9451 tablet
- A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis CCompletedPhase 2Gilead SciencesNCT01271790Written as GS-9451
- GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C VirusCompletedPhase 2Gilead SciencesNCT01356160Written as GS-9451
- GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC GenotypeTerminatedPhase 2Gilead SciencesNCT01384383Written as GS-9451
- GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) InfectionCompletedPhase 2Gilead SciencesNCT01353248Written as GS-9451
Given in every arm · 3 — GS-9451 is usual care beside what is tested
- Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and CirrhosisCompletedPhase 2Gilead SciencesNCT02226549Written as VDV
- GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) InfectionCompletedPhase 2Gilead SciencesNCT01434498Written as GS-9451 tablet
- GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) InfectionCompletedPhase 2Gilead SciencesNCT01435226Written as GS-9451